Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2023 Annual Meeting

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced that the company and its collaborators will present a total of 12 abstracts accepted for poster discussion, presentation, and online publication at this year's American Society of Clinical Oncology (ASCO) Annual meeting, to be held in Chicago this June.

"As demonstrated by our presence at ASCO this year, Flatiron is continuing to scale our ability to connect powerful data and novel technology to better design trials for diversity, accelerate clinical research timelines, reduce burden across teams and complete trials with more confidence," shares Flatiron Health Chief Medical Officer Javier Jimenez. "Aligned with this year's theme, Flatiron's intimate knowledge of the oncology healthcare ecosystem and multi-faceted and deep understanding of EHR data positions us to continue developing technology and driving research to close the gap between care and research."

Research highlights include:

• A Poster Discussion Session highlighting the mediators of racial and ethnic inequities in clinical trial participation among US patients with cancer.
• An Oral Abstract Session discussing a collaboration between Flatiron Health and Foundation Medicine to measure tumor mutational burden (TMB) from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.
• An Oral Abstract Session discussing research done by the Health Equity One-Roche Collaboration (Flatiron Health, West Clinic, OneOncology, Foundation Medicine, and Genentech) to understand practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients with advanced non-small cell lung cancer (aNSCLC) treated in the community setting. This study was invited to submit a manuscript for simultaneous publication in the Journal of Clinical Oncology - Oncology Practice.

Learn more about our abstracts and events by visiting our website.

Follow Flatiron Health on Twitter and LinkedIn for more updates from #ASCO23 and visit us in person at Booth #23127.

Poster Discussions and Presentations

Mediators of racial/ethnic inequities in clinical trial participation among US patients with cancer, 2011-2022.
Poster Discussion Session

More on EntSun News

• California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
• Performance Slots Available: Collision Course Concert Series Heads to Atlanta, Tampa & Brooklyn
• Rent Like A Champion Acquires CollegeWeekends
• Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
• Seligson Law Launches New Website to Support Cannabis Businesses in California and New York

Jenny S. Guadamuz, Xiaoliang Wang, Ivy Altomare, Gregory S. Calip

Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types
Oral Abstract Session
Partner: Foundation Medicine
David R. Gandara, Neeraj Agarwal, Shilpa Gupta, Samuel Klempner, Miles Andrews, Amit Mahipal, Vivek Subbiah, Ramez Eskander, David Carbone, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Gerald Li, Julia C. F. Quintanilha, Richard S.P. Huang, Jeffrey S. Ross, David Fabrizio, Geoffrey R. Oxnard, Ryon P. Graf

Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting.
Oral Abstract Session
Partner: Health Equity One-Roche Collaboration — Flatiron Health, West Clinic, OneOncology, Foundation Medicine, and Genentech
Gregory Vidal, Neha Jain, Aaron Fisher, Danny Sheinson, Katherine T. Lofgren, Esprit Ma, Elaine Yu, Leah Comment, Rebecca Miksad, Davey Daniel

Technology-enabled clinical trials: Intentional capture of source data (IDC) in the electronic-health record (EHR) and direct transfer to trial database (electronic data capture [EDC]) in a phase II multicenter trial.
Trevor J. Royce, Sam Falk, Forrest Xiao, Mariel Boyd, Lindsay Bramwell, Addison Shelley, Lauren Sutton, Ruth M Morgan, Patricia Mader, Teresa Taiclet, Abigail Alve

Trial eligibility criteria (EC) and diversity among patients with advanced non small cell lung cancer (advNSCLC).
Maneet Kaur, Filip Frahm, Mustafa Ascha, Jenny Guadamuz, Adam Gottesman, Barry Leybovich, Arjun Sondhi, Yihua Zhao, Neal J. Meropol, Trevor Royce

More on EntSun News

• databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
• AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
• The Recording Academy Extends Invitation to The World's No.1 Superstar™—But He's Not Chasing the Award
• WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
• CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond

Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC).
Qianyu Yuan, Emily Castellanos, Erin Fidyk, Karen Schwed, Melissa Estevez, Sheila Nemeth, Robin Linzmayer, and Aaron Cohen

Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets.
Partner: Friends of Cancer Research (FoCR) — FDA, Flatiron Health, Syapse, Cota, ConcertAI, McKesson, Tempus
Xinran Ma, Friends of Cancer Research, ASCO, FDA, ConcertAI, COTA, Guardian Research Network, IQVIA, Ontada, Syapse, and Tempus

Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.
Partner: Foundation Medicine
Debra Richardson, Julia Quintanilha, Ryon Graf, Natalie Danziger, Christina Washington, Lauren Dockery, Tamara Snow, Anosheh Afghahi, Anthony Frachioni, Julia Elvin, Kathleen Moore

Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.
Partner: Yale University
Maureen Canavan*, Xiaoliang Wang*, Mustafa Ascha, Rebecca Miksad, Timothy N. Showalter, Gregory Calip , Cary P. Gross, Kerin Adelson
*These authors contributed equally to the work.

Evaluating Generalizability of Practice-Changing Randomized Clinical Trials in Non-Small Cell Lung Cancer using Machine Learning-Based In-Silico Trials.
Partner: University of Pennsylvania
Ravi Parikh, Xavier Orcutt, Arjun Sondhi, Aaron Cohen

Clinical pathways innovation: A lesson on the value of clinician based feedback and collaboration with Flatiron Health
Partner: University of Pennsylvania
Christopher D'Avella, Erin Bange, Aditi Singh, David Dougherty, Peter Gabriel, Rebecca Maniago, Jennifer Miao, Colin Harvey, Marcello Ricottone, Lawrence N. Shulman

About Flatiron Health

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

Contacts

Flatiron Health
Nina Toor
communications@flatiron.com

---

Show All News | Report Violation